Sign in
Active, not recruitingNo phase

Long-term Follow-Up for RGX-121

Key facts

Who runs it
REGENXBIO Inc.
Where
New Brunswich, Philadelphia, and San Francisco, United StatesSee the 3 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
People taking part
27 people enrolled
Started
14 Mar 2021
Expected to end
Oct 2028
Type of study
Observational
Treatments tested
  • Long-term Follow-Up
Record updated
19 August 2026

Who can take part

Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • To be eligible, a participant must have previously received RGX-121 in a separate parent trial
  • Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent

Who cannot take part

  • Participant has not received RGX-121 previously in a separate parent trial

Where in United States

Also in 1 other country, 1 site

  • Saint Peter's Healthcare SystemNew Brunswich, United States
  • The Children's Hospital of Philadelphia (CHOP)Philadelphia, United States
  • University of California, San Francisco (UCSF) Benioff Children's HospitalSan Francisco, United States

About the trial

What the trial wants to find out

RGX-121-5101 is an observational long-term follow-up study to the RGX-121-101 or RGX-121-1102 studies where participants received RGX-121, a gene therapy intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study will evaluate the long-term safety and efficacy of RGX-121.

The group in the trial

  • Long-term Follow-Up

    No intervention.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-121
Record updated
19 August 2026